Drug Resistance Predictions Based on a Directed Flag Transformer

Dong Chen; Gengzhuo Liu; Hongyan Du; Benjamin Jones; Junjie Wee; Rui Wang; Jiahui Chen; Jana Shen; Guo-Wei Wei

Home/Archive/arXiv

arXiv · 2403.02603

Drug Resistance Predictions Based on a Directed Flag Transformer

Dong Chen·Gengzhuo Liu·Hongyan Du·Benjamin Jones·Junjie Wee·Rui Wang·Jiahui Chen·Jana Shen·Guo-Wei Wei

View original source ↗Read source document ↗Export metadata ↓

Abstract

The continuous evolution of the SARS-CoV-2 virus poses a significant challenge to global public health. Of particular concern is the potential resistance to the widely prescribed drug PAXLOVID, of which the main ingredient nirmatrelvir inhibits the viral main protease (Mpro). Here, we developed CAPTURE (direCted flAg laPlacian Transformer for drUg Resistance prEdictions) to analyze the effects of Mpro mutations on nirmatrelvir-Mpro binding affinities and identify potential drug-resistant mutations. CAPTURE combines a comprehensive mutation analysis with a resistance prediction module based on DFFormer-seq, which is a novel ensemble model that leverages a new Directed Flag Transformer and sequence embeddings from the protein and small-molecule-large-language models. Our analysis of the evolution of Mpro mutations revealed a progressive increase in mutation frequencies for residues near the binding site between May and December 2022, suggesting that the widespread use of PAXLOVID created a selective pressure that accelerated the evolution of drug-resistant variants. Applied to mutations at the nirmatrelvir-Mpro binding site, CAPTURE identified several potential resistance mutations, including H172Y and F140L, which have been experimentally confirmed, as well as five other mutations that await experimental verification. CAPTURE evaluation in a limited experimental data set on Mpro mutants gives a recall of 57\% and a precision of 71\% for predicting potential drug-resistant mutations. Our work establishes a powerful new framework for predicting drug-resistant mutations and real-time viral surveillance. The insights also guide the rational design of more resilient next-generation therapeutics.

Explore related subjects

q-bio.QM

Keep this discovery

BibTeX RIS

Dong Chen, Gengzhuo Liu, Hongyan Du, Benjamin Jones, Junjie Wee, Rui Wang, Jiahui Chen, Jana Shen, Guo-Wei Wei. 2024-03-05. Drug Resistance Predictions Based on a Directed Flag Transformer. https://arxiv.org/abs/2403.02603

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related papers

arXiv2026

Biology-in-the-loop: Amortized Adaptive Hit Discovery in CRISPR Screens

Many biological discovery problems require experiments to be selected sequentially under constrained budgets. CRISPR screening is a prominent example, as exhaustive perturbation testing is often infeasible and candidate perturbations must instead be prioritized over multiple experimental rounds. Despite the importance of this problem, existing benchmarks for adaptive hit discovery remain limited in scale and diversity. Here, we introduce AssayBench-Loop, a large-scale benchmark for adaptive hit discovery comprising 1,389 CRISPR screens across five phenotype categories. Beyond enabling systematic evaluation, its scale makes it possible to learn acquisition strategies across historical experiments. Building on this resource, we introduce AssayLoop, a sequential experimental design framework combining AssayFormer, a transformer-based amortized acquisition policy trained across historical screens to adapt from experimental feedback, with LLM-derived biological priors through an adaptive handoff. In this view, completed experiments become training data for learning how accumulated evidence should guide what to test next, while LLMs provide prior biological knowledge to seed the search. We further introduce AssayLLM, showing that the same principle can be extended directly to an LLM through task-specific post-training. On temporally held-out screens, AssayLoop achieves a 5.67-fold enrichment over random selection and recovers 27.7% of hits after assaying approximately 5% of the candidate library, outperforming existing adaptive-design methods and standalone LLMs, and AssayFormer alone. Performance improves with increasing historical training data and transfers to phenotype categories excluded from training. These results demonstrate the value of learning acquisition policies across historical experiments and combining them with broad biological priors for efficient adaptive hit discovery.

q-bio.QM↗

arXiv2026

Multi-Task Bacterial Colony Detection and Classification Using YOLOv8 with Edge Optimization for Resource-Constrained Deployment

Manual counting and classification of bacterial colonies are critical yet labor-intensive tasks in microbiology, prone to human error particularly on densely populated plates. This work proposes a multi-task deep learning framework trained on the Annotated Germs for Automated Recognition (AGAR) dataset (18,000 images; 9,202 training / 3,067 testing) to automate Colony Forming Unit (CFU) enumeration and species classification. A custom multi-task CNN employing global regression served as the baseline, but demonstrated limited performance in clustered colony environments due to the absence of spatial localization. To address this, a YOLOv8 object detection architecture was adopted with high-resolution 1024x1024 inputs, enabling instance-level colony detection and label assignment. The model achieved a classification accuracy of 98.13% and a counting accuracy of 98.27% (within a 10-colony margin), demonstrating strong predictive capability. To bridge the gap between model performance and practical deployability, the trained model was optimized through unstructured and structured pruning, ONNX conversion, and reduced-precision inference (FP32, FP16, INT8). On a Raspberry Pi 4B, ONNX FP32 and FP16 variants offered the best balance between inference speed (~6.4s) and accuracy (MAE ~2.20). Unstructured pruning preserved predictive accuracy (MAE ~2.01) without runtime gains, while structured pruning resulted in significant accuracy degradation (MAE ~6.3), revealing the sensitivity of instance-level colony detection to architectural compression. These findings provide practical guidance for selecting optimization strategies in resource-constrained laboratory deployments.

q-bio.QM↗

arXiv2026

ADMET-EvO: a self-evolving scientific agent for sustained research across heterogeneous tasks

Scientific agents can move beyond automated model building by using accumulated evidence to revise both their questions and experimental strategies. The challenge is sustaining this adaptation across heterogeneous tasks without overfitting decisions to internal validation. Absorption, distribution, metabolism, excretion and toxicity (ADMET) prediction provides a demanding setting across diverse assays, datasets and chemical domains. We therefore developed ADMET-EvO, an evidence-gated agent that formalizes endpoints, generates falsifiable hypotheses and tests interventions across data, feature and model axes. It carries supported, rejected and inconclusive outcomes forward to guide each new cycle. Across the 22-task Therapeutics Data Commons (TDC) ADMET benchmark, ADMET-EvO achieved the highest task-normalized score of 96.77. Evidence-guided selection reduced cumulative fitting time by 72.2% within a predefined non-inferiority margin. It also formalized 43 toxicity-related tasks and constructed endpoint-specific predictors. Together, these results show how ADMET-EvO can accumulate evidence, revise its strategy and expand its research scope over time.

q-bio.QM↗